• U Bender, Y S Rho, I Barrera, S Aghajanyan, J Acoba, and P Kavan.
• Gerald Bronfman Department of Oncology, McGill University Faculty of Medicine, Montreal, QC.
• Curr Oncol. 2019 Nov 1; 26 (Suppl 1): S43-S52.

BackgroundTo date, the role of adjuvant systemic therapy in stages ii and iii colon cancer remains a topic of interest and debate. The objective of the present review was to assess the most recent data, specifically addressing methods of risk stratification, duration of therapy, and future directions.MethodsPubMed and medline were searched for literature pertinent to adjuvant chemotherapy in either stage ii or stage iii colorectal cancer.SummaryLocoregional disease, histopathology, age, laterality, and a number of other biologic and molecular markers appear to have a role in disease risk stratification. The duration of adjuvant therapy for stage iii disease can vary based on risk factors, but use of adjuvant therapy and duration of therapy in stage ii disease remain controversial. Future directions should include genomic assays and improved study design to provide concrete evidence about the duration of adjuvant folfox or capox and about other types of chemotherapy and immunotherapy.2019 Multimed Inc.

12 keywords...

hide…